Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dermcidin (DCD) is a secreted human protein, predominantly expressed in eccrine sweat glands, and processed into multiple bioactive peptides[5][6]. Its primary role is as an anionic antimicrobial peptide (AMP) that directly disrupts bacterial and fungal cells by forming Zn²⁺-stabilized oligomeric channels in microbial membranes; these ion channels inhibit vital cellular functions resulting in pathogen death[1][3][7]. DCD-derived peptides also play key roles in human biology, such as promoting neural cell survival under stress (N-terminal domain) and inducing muscle proteolysis linked to cancer cachexia (PIF domain)[5][6]. Furthermore, DCD has been investigated as a putative oncogene for its ability to enhance tumor cell survival and proliferation, likely via regulation of pro-growth signaling networks such as VEGFB[2][3]. DCD and its processed peptides are stable in sweat and constitute part of the body’s constitutive, non-inducible innate skin defense system; reduced levels are linked to higher risk of skin infections such as atopic dermatitis and tinea pedis[1][3]. There are promising therapeutic opportunities and challenges for targeting DCD or harnessing its activity, but no approved interacting drugs at present[4].
Antimicrobial: Oligomerizes (Zn²⁺-dependent), inserts into microbial membranes, forms ion channels, disrupts ionic homeostasis, inhibits DNA/RNA/protein synthesis, induces cell death. Survival promotion: N-terminal peptide protects neural cells from oxidative stress. Cachexia: PIF domain induces muscle proteolysis in cancer. Oncogenic: Putative, via upregulation of proliferative pathways in tumor cells (e.g., VEGFB hub).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dermcidin (DCD).